Pembrolizumab in hemodialysis patients. Is it safe?

Pembrolizumab in hemodialysis patients. Is it safe?

Bibliographic Details
Main Authors:	Melisa Guzmán Vasquez, Andrea Patricia Zapata Balcázar, Daniel Germán Gaitán Tocora, Concepción Álamo Caballero, José Ramón Rodríguez Palomares, Marta Sánchez Heras, Gabriel de Arriba de La Fuente
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	Nefrología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2013251420301486

Similar Items

Pembrolizumab en pacientes en hemodiálisis ¿es seguro?
by: Melisa Guzmán Vasquez, et al.
Published: (2020-11-01)

POS-563 PREVALENCE OF COVID 19 IN A HOSPITAL HEMODIALYSIS UNIT
by: N. Begoña Boldoba, et al.
Published: (2021-04-01)

Epicardial fat tissue, coronary arterial calcification and mortality in patients with advanced chronic kidney disease and hemodialysis
by: Marta Cano Megías, et al.
Published: (2021-03-01)

Atypical Stevens–Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma – Are corticosteroids a safe treatment option?
by: Cathal O'Connor, et al.
Published: (2020-01-01)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
by: Yuki Katsumata, et al.
Published: (2021-10-01)

Regional citrate anticoagulation for hemodialysis: A safe and efficient method
by: Jarraya Faical, et al.
Published: (2010-01-01)

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
by: Marcela Carausu, et al.
Published: (2019-11-01)

Pembrolizumab-induced Pneumonitis
by: Joshua Busken
Published: (2023-05-01)

Pembrolizumab-induced pneumonitis
by: Vincent Leroy, et al.
Published: (2017-05-01)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022-12-01)

Is dialysis water a safe component for hemodialysis treatment in São Paulo State, Brazil?
by: Ellen Gameiro Hilinski, et al.
Published: (2020-04-01)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
by: Noemí Puig, et al.
Published: (2020-12-01)

Glomerulonefritis extracapilar y lepra: una asociación infrecuente
by: Gabriel de Arriba, et al.
Published: (2016-05-01)

Extracapillary glomerulonephritis and leprosy: An uncommon association
by: Gabriel de Arriba, et al.
Published: (2016-05-01)

Evaluation of dosing strategy for pembrolizumab for oncology indications
by: Tomoko Freshwater, et al.
Published: (2017-05-01)

Educating your patient is cost-effective: It reduces serum phosphate and saves €200 per patient per month
by: José R. Rodriguez-Palomares, et al.
Published: (2017-01-01)

Las estrategias de educación a pacientes son coste efectivas: reduzca el fósforo ahorrando 200 € al mes por paciente
by: José R. Rodriguez-Palomares, et al.
Published: (2017-01-01)

Molecular Farming of Pembrolizumab and Nivolumab
by: Michael C. Stark, et al.
Published: (2023-06-01)

Neoadjuvant pembrolizumab in advanced melanoma
by: Praful Pandey, et al.
Published: (2023-01-01)

Pembrolizumab as adjuvant therapy in melanoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Pembrolizumab reactivates pulmonary granulomatosis
by: Majdi Al-dliw, et al.
Published: (2017-01-01)

Mortality of hemodialysis patients is associated with their clinical situation at the start of treatment
by: Gabriel de Arriba, et al.
Published: (2021-07-01)

Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature
by: Jae Won Yun, et al.
Published: (2023-02-01)

Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis
by: Wai-Nga Chan, et al.
Published: (2022-09-01)

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer
by: Denise Uyar, et al.
Published: (2024-02-01)

1240 Safety profile of pembrolizumab monotherapy versus pembrolizumab with combined treatments: analysis of french pharmacovigilance database
by: Laure Thomas, et al.
Published: (2023-11-01)

Pembrolizumab-Induced Toxic Epidermal Necrolysis
by: Luca Borg, et al.
Published: (2022-10-01)

Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab
by: Andrew Sanchez, et al.
Published: (2022-11-01)

Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
by: Tiffany T. Oommen, et al.
Published: (2023-01-01)

Spotlight on pembrolizumab in the treatment of advanced melanoma
by: Rajakulendran T, et al.
Published: (2015-06-01)

Posterior reversible encephalopathy associated with pembrolizumab
by: Á. Lambea-Gil, et al.
Published: (2021-09-01)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
by: Hao‐Chun Chang, et al.
Published: (2020-08-01)

Pembrolizumab Treatment-Induced Liver Toxicity
by: Benoît Calderon, et al.
Published: (2021-08-01)

Pembrolizumab-Induced Delayed-Onset Hepatitis
by: Kensuke Kanaoka, et al.
Published: (2020-11-01)

Diabetic ketoacidosis after treatment with pembrolizumab
by: M. Hariz. F. Abdul Aziz, et al.
Published: (2017-09-01)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
by: Giulio Rizzetto, et al.
Published: (2023-08-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
by: Rita Chiari, et al.
Published: (2023-11-01)

Modelo de recertificación: una oportunidad para los nefrólogos
by: Gabriel de Arriba
Published: (2023-12-01)